Literature DB >> 32147848

Challenge of parents caring for children or adolescents with early-stage schizophrenia in China: A qualitative study.

Xiao-Ling Bai1, Zhong-Chen Luo2, Anni Wang3, Zi-Yao Guan4, Zhao-Yang Zhong5, Mei Sun4, Si-Yuan Tang4.   

Abstract

PURPOSE: To explore the challenges of parents caring for early-stage schizophrenia (ESS) children/adolescents in China. DESIGN AND METHODS: Thirteen parents of ESS subjects completed semi-structured interviews. Thematic analysis was used to analyze data.
FINDINGS: Seven themes emerged from the data: psychological shock and emotional burden; lack of disease knowledge and care skill; poor treatment compliance of the patient; difficulty getting along with the patient; conflict within the family or in the workplace; financial burden; and need sufficient social support. Each challenge was produced and influenced under the Chinese special social context. PRACTICE IMPLICATIONS: Professional support was needed to help patients with schizophrenia to cope with their situation promptly. Education initiatives should focus on mental health to prevent discrimination from society and enable people to recognize the early symptoms of schizophrenia in children. Telemedicine should be explored for application in the treatment of mental illness. Also, a broader nationwide healthcare policy would be needed to help to reduce the individual and societal financial burdens associated with schizophrenia.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  adolescent; challenge; child; parent; schizophrenia

Mesh:

Year:  2020        PMID: 32147848     DOI: 10.1111/ppc.12492

Source DB:  PubMed          Journal:  Perspect Psychiatr Care        ISSN: 0031-5990            Impact factor:   2.186


  1 in total

1.  Stakeholder Perspectives on Barriers and Facilitators for the Adoption of Virtual Clinical Trials: Qualitative Study.

Authors:  Romée Melanie Helena Coert; James Kenneth Timmis; André Boorsma; Wilrike J Pasman
Journal:  J Med Internet Res       Date:  2021-07-06       Impact factor: 5.428

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.